SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway
Abstract The development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established. Herein, we found that overactivation of SRC is associated with cisplatin-resist...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-024-07284-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544370553094144 |
|---|---|
| author | Yuwen Gong Dongyang Gao Yibo Shi Guangrui Fan Xiaoquan Yu Enguang Yang Hui Cheng Junqiang Tian Hui Ding Shanhui Liu Shengjun Fu Yan Tao Yuan Shui Liang Cheng Lanlan Li Zhiping Wang |
| author_facet | Yuwen Gong Dongyang Gao Yibo Shi Guangrui Fan Xiaoquan Yu Enguang Yang Hui Cheng Junqiang Tian Hui Ding Shanhui Liu Shengjun Fu Yan Tao Yuan Shui Liang Cheng Lanlan Li Zhiping Wang |
| author_sort | Yuwen Gong |
| collection | DOAJ |
| description | Abstract The development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established. Herein, we found that overactivation of SRC is associated with cisplatin-resistance. SRC activates hexokinase2 which up-regulates glycolysis and especially the pentose phosphate pathway that leading to increased nucleotide synthesis and NADPH production which can neutralize reactive oxygen species (ROS) induced by cisplatin, thereby protecting bladder cancer cells from cisplatin-induced DNA damage. This phenomenon was effectively reversed by knockout of SRC and inhibition of SRC activity by the SRC inhibitor, eCF506. Moreover, we constructed Cell-derived xenograft (CDX) and Patient-derived xenograft (PDX) from cisplatin-resistant bladder cancer patient. eCF506 exhibited excellent anti-tumor effects and effectively enhanced cisplatin-sensitivity. Altogether, our findings demonstrate that targeting SRC is a promising approach to overcome cisplatin-resistance in bladder cancer, and providing new insights for combination therapy in bladder cancer. |
| format | Article |
| id | doaj-art-87dbe297e73e4668b64ec4a0abe3f674 |
| institution | Kabale University |
| issn | 2399-3642 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Biology |
| spelling | doaj-art-87dbe297e73e4668b64ec4a0abe3f6742025-01-12T12:35:38ZengNature PortfolioCommunications Biology2399-36422025-01-018111510.1038/s42003-024-07284-1SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathwayYuwen Gong0Dongyang Gao1Yibo Shi2Guangrui Fan3Xiaoquan Yu4Enguang Yang5Hui Cheng6Junqiang Tian7Hui Ding8Shanhui Liu9Shengjun Fu10Yan Tao11Yuan Shui12Liang Cheng13Lanlan Li14Zhiping Wang15Institute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterDepartment of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Albert Medical School, Brown University HealthInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterInstitute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical CenterAbstract The development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established. Herein, we found that overactivation of SRC is associated with cisplatin-resistance. SRC activates hexokinase2 which up-regulates glycolysis and especially the pentose phosphate pathway that leading to increased nucleotide synthesis and NADPH production which can neutralize reactive oxygen species (ROS) induced by cisplatin, thereby protecting bladder cancer cells from cisplatin-induced DNA damage. This phenomenon was effectively reversed by knockout of SRC and inhibition of SRC activity by the SRC inhibitor, eCF506. Moreover, we constructed Cell-derived xenograft (CDX) and Patient-derived xenograft (PDX) from cisplatin-resistant bladder cancer patient. eCF506 exhibited excellent anti-tumor effects and effectively enhanced cisplatin-sensitivity. Altogether, our findings demonstrate that targeting SRC is a promising approach to overcome cisplatin-resistance in bladder cancer, and providing new insights for combination therapy in bladder cancer.https://doi.org/10.1038/s42003-024-07284-1 |
| spellingShingle | Yuwen Gong Dongyang Gao Yibo Shi Guangrui Fan Xiaoquan Yu Enguang Yang Hui Cheng Junqiang Tian Hui Ding Shanhui Liu Shengjun Fu Yan Tao Yuan Shui Liang Cheng Lanlan Li Zhiping Wang SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway Communications Biology |
| title | SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway |
| title_full | SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway |
| title_fullStr | SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway |
| title_full_unstemmed | SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway |
| title_short | SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway |
| title_sort | src enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway |
| url | https://doi.org/10.1038/s42003-024-07284-1 |
| work_keys_str_mv | AT yuwengong srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT dongyanggao srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT yiboshi srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT guangruifan srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT xiaoquanyu srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT enguangyang srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT huicheng srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT junqiangtian srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT huiding srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT shanhuiliu srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT shengjunfu srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT yantao srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT yuanshui srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT liangcheng srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT lanlanli srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway AT zhipingwang srcenhancedcisplatinresistanceinbladdercancerbyreprogrammingglycolysisandpentosephosphatepathway |